SAN FRANCISCO, Jan. 25 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. , a leading RNAi therapeutics company, announced today that Howard W. Robin, Sirna’s President and Chief Executive Officer, is scheduled to present at the Brean Murray, Carret Small Cap Institutional Investor Conference on Wednesday, February 1, 2006 at 11:30 a.m. EST (9:30 a.m. MST; 8:30 a.m. PST) at the Grand Hyatt Hotel in New York City.
A live audio webcast of the presentation will be available at the Company’s corporate web site at www.sirna.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. The webcast will also be archived on the Company’s web site for 30 days.
About Sirna Therapeutics
Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington’s disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., continues to demonstrate that it is safe and well tolerated with 100% of patients showing visual acuity stabilization after eight weeks from a single injection. In addition, Sirna recently announced that it has selected Sirna-AV34, a systemically delivered, optimized siRNA compound, as its candidate for advancement to human clinical testing against Hepatitis C virus. Sirna has a leading intellectual property portfolio in RNAi with 49 issued patents and over 240 pending applications worldwide. More information on Sirna Therapeutics is available on the Company’s web site at http://www.sirna.com.
Contacts: J. Michael French Senior Vice President, Corporate Development Sirna Therapeutics, Inc., (303) 449-6500 Investors Francesca DeMartino The Ruth Group (646) 536-7024 fdemartino@theruthgroup.com Media Jason Rando The Ruth Group (646) 536-7025 jrando@theruthgroup.com
Sirna Therapeutics, Inc.
CONTACT: J. Michael French, Senior Vice President, Corporate Developmentof Sirna Therapeutics, Inc., +1-303-449-6500; or Investors, FrancescaDeMartino, +1-646-536-7024, fdemartino@theruthgroup.com, or Media, JasonRando, +1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group,for Sirna Therapeutics, Inc.
Web site: http://www.sirna.com//
